LabLogic radiochromatography systems assist cancer antibody trials

LabLogic radiochromatography systems assist cancer antibody trials
The School of Medicine at the UK's Southampton University is using radio HPLC and radio TLC systems from LabLogic in connection with clinical trials for treating haematological malignancies.
 
FOR IMMEDIATE RELEASE

PRLog (Press Release) - Nov 30, 2010 - The Cancer Sciences Division of Southampton University School of Medicine is using radio HPLC and radio TLC systems from LabLogic in the development and quality control of radio-labelled antibody conjugates undergoing clinical trials for treating haematological malignancies.

The HPLC system incorporates an Agilent quaternary pump, an auto-degasser and a thermostatically controlled column compartment.

"We have had the equipment for ten months now, and it has proved to be a sensitive and reliable upgrade from our previous system," says John Langford, head of the laboratory.

"It is always easy to use, whether we are measuring the gamma emissions of indium-111 or the beta emissions of yttrium-90.  And the speed and ease of use of LabLogic's Laura radiochromatography software means that results are available immediately after the end of each run.

"We often correlate our results to ITLC for confirmation, and here we're finding that the LabLogic radio-TLC scanner provides more detail than the ‘cut and count' method.  It makes it easier to locate peaks and discriminate between them and it uses the same Laura software, which is very convenient."

# # #


LabLogic Systems has been supplying nucleonic instrumentation and scientific software since 1979. Principal clients are pharmaceutical, agrochemical and contract research organisations, who use the company's products in their research and development activities.

--- end ---

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.